A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956) Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma, Bronchiolo-Alveolar
  • Antineoplastic Agents, Phytogenic
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Paclitaxel

abstract

  • Paclitaxel as single agent in stages IIIB-IV BAC was well tolerated and manageable but of limited efficacy. BAC should not be excluded from trials of new forms of chemotherapy.

publication date

  • October 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.lungcan.2005.05.012

PubMed ID

  • 16019107

Additional Document Info

start page

  • 91

end page

  • 6

volume

  • 50

number

  • 1